Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-3079 in B-Cell Non-Hodgkin Lymphoma
NCT07661537Phase 1Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-3079 in B-cell non-Hodgkin lymphoma, sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Dose-limiting Toxicity at 28 days, Maximum Tolerated Dose at 1 year and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
SHR-3079
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07661537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07661537.